FDA Clearance Tracker · P850048-S060
Access Hybritech PSA
Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Sep 4, 2024
Approved
Time to decision
160 days
Received Mar 28, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P850048-S060
- Device name
- Access Hybritech PSA
- Applicant
- Beckman Coulter, Inc.
- Applicant location
- Brea, CA
- Received
- Mar 28, 2024
- Decided
- Sep 4, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P850048
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Migration of the Access Hybritech PSA to the DxI 9000 Access Immunoassay Analyzer.
Source documents
Other decisions for Beckman Coulter, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Access BNP II510(k)
K262597 · Decided Oct 20, 2026 · 85 days after receipt
Device type: Test, Natriuretic Peptide (NBC) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.